Find Lazertinib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1903008-80-9, Yh-25448, Gns-1480, Yh25448, Gns1480, Jnj-73841937-aaa
Molecular Formula
C30H34N8O3
Molecular Weight
554.6  g/mol
InChI Key
RRMJMHOQSALEJJ-UHFFFAOYSA-N
FDA UNII
4A2Y23XK11

Lazertinib
Lazertinib is an orally available third-generation, selective inhibitor of certain forms of the epidermal growth factor receptor (EGFR) with activating mutations, including the resistance mutation T790M, exon 19 deletions (Del19), and the L858R mutation, with potential antineoplastic activity. Upon administration, lazertinib specifically and irreversibly binds to and inhibits selective EGFR mutants, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Lazertinib may inhibit programmed cell death-1 ligand 1 (PD-L1) and inflammatory cytokines in specific cancer cells harboring certain EGFR mutations. Compared to some other EGFR inhibitors, lazertinib may have therapeutic benefits in tumors with T790M- or L858R-mediated drug resistance. In addition, lazertinib penetrates the blood-brain barrier (BBB). This agent shows minimal activity against wild-type EGFR (wtEGFR), and does not cause dose-limiting toxicities, which occur during the use of non-selective EGFR inhibitors and inhibit wtEGFR. EGFR, a receptor tyrosine kinase (RTK) mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.
1 2D Structure

Lazertinib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-[5-[[4-[4-[(dimethylamino)methyl]-3-phenylpyrazol-1-yl]pyrimidin-2-yl]amino]-4-methoxy-2-morpholin-4-ylphenyl]prop-2-enamide
2.1.2 InChI
InChI=1S/C30H34N8O3/c1-5-28(39)32-23-17-24(26(40-4)18-25(23)37-13-15-41-16-14-37)33-30-31-12-11-27(34-30)38-20-22(19-36(2)3)29(35-38)21-9-7-6-8-10-21/h5-12,17-18,20H,1,13-16,19H2,2-4H3,(H,32,39)(H,31,33,34)
2.1.3 InChI Key
RRMJMHOQSALEJJ-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CN(C)CC1=CN(N=C1C2=CC=CC=C2)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N5CCOCC5)OC
2.2 Other Identifiers
2.2.1 UNII
4A2Y23XK11
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 2-propenamide, N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)-2-pyrimidinyl)amino)-4-methoxy-2-(4-morpholinyl)phenyl)-

2. Leclaza

3. N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)-2-pyrimidinyl)amino)-4-methoxy-2-(4-morpholinyl)phenyl)acrylamide

2.3.2 Depositor-Supplied Synonyms

1. 1903008-80-9

2. Yh-25448

3. Gns-1480

4. Yh25448

5. Gns1480

6. Jnj-73841937-aaa

7. Lazertinib [usan]

8. C-18112003-g

9. N-[5-[[4-[4-[(dimethylamino)methyl]-3-phenylpyrazol-1-yl]pyrimidin-2-yl]amino]-4-methoxy-2-morpholin-4-ylphenyl]prop-2-enamide

10. 4a2y23xk11

11. N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-methoxy-2-morpholinophenyl)acrylamide

12. 2-propenamide, N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)-2-pyrimidinyl)amino)-4-methoxy-2-(4-morpholinyl)phenyl)-

13. Leclaza

14. Lazertinib [inn]

15. Lazertinib [inn]

16. Lazertinib (yh25448)

17. Lazertinib [who-dd]

18. Unii-4a2y23xk11

19. Chembl4558324

20. Schembl17670400

21. Gtpl10136

22. Bcp30440

23. Ex-a1912

24. Bdbm50555575

25. S8724

26. Who 10587

27. Akos037515597

28. Ccg-270023

29. Lazertinib (yh25448,gns-1480)

30. Yh-25448;gns-1480

31. Ac-36243

32. Bs-15742

33. Compound 73 [wo2016060443a2]

34. Hy-109061

35. Cs-0032992

36. A16827

37. A903188

38. Yh-25448; Yh 25448; Yh25448; Gns-1480; Gns 1480; Gns1480

39. N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)-2-pyrimidinyl)amino)-4-methoxy-2-(4-morpholinyl)phenyl)acrylamide

40. N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide

2.4 Create Date
2016-08-06
3 Chemical and Physical Properties
Molecular Weight 554.6 g/mol
Molecular Formula C30H34N8O3
XLogP33.4
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count9
Rotatable Bond Count10
Exact Mass554.27538698 g/mol
Monoisotopic Mass554.27538698 g/mol
Topological Polar Surface Area110 Ų
Heavy Atom Count41
Formal Charge0
Complexity837
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Protein Kinase Inhibitors

Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)


API Reference Price

read-more
read-more
[{"dataSource":"API Import","activeIngredients":"LAZERTINIB","year":"2021","qtr":"Q1","strtotime":1611253800,"product":"(N.C.V) (JNJ-73858434-AAA) INTERMEDIATE OF LAZERTINIB (FOR R&D UNIT ONLY)","address":"30 FORJETT STREETPOST BOX NO 9301","city":"MUMBAI, MAHARASHTRA.","supplier":"JOHNSON & JOHNSON","supplierCountry":"CHINA","foreign_port":"BRUSSELS","customer":"JOHNSON & JOHNSON","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.2","unit":"GMS","unitRateFc":"286","totalValueFC":"70.5","currency":"EUR","unitRateINR":"25782.9","date":"22-Jan-2021","totalValueINR":"5156.58","totalValueInUsd":"70.5","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"2458573","productDescription":"Intermediate","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BRUSSELS","supplierAddress":"","customerAddress":"30 FORJETT STREETPOST BOX NO 9301"},{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q2","strtotime":1624645800,"product":"(N.C.V) REF.STD. LAZERTINIB (JNJ-73841937-ZCY)R605024 2-PROPENAMIDE,N-[5-[[4-[4-(DIMETHYLAMINO)METHYL]-3-PHENYL-1H-PYRAZ","address":"30 FORJETT STREETPOST BOX NO 9301","city":"MUMBAI, MAHARASHTRA.","supplier":"JOHNSON & JOHNSON","supplierCountry":"BELGIUM","foreign_port":"BRUSSELS","customer":"JOHNSON & JOHNSON","customerCountry":"INDIA","quantity":"0.04","actualQuantity":"40.044","unit":"GMS","unitRateFc":"286","totalValueFC":"14014.9","currency":"EUR","unitRateINR":"25740","date":"26-Jun-2021","totalValueINR":"1030732.2","totalValueInUsd":"14014.9","indian_port":"BOMBAY AIR","hs_no":"29349990","bill_no":"4466841","productDescription":"API","marketType":"REGULATED MARKET","country":"BELGIUM","selfForZScoreResived":"Pharma Grade","supplierPort":"BRUSSELS","supplierAddress":"","customerAddress":"30 FORJETT STREETPOST BOX NO 9301"},{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1630434600,"product":"(N.C.V) LAZERTINIB (JNJ-73841937-ZCY)R605024.REF.STD. 2-PROPENAMIDE,N[5-[[4-[4-[(DIMETHYLAMINO)METHYL]-3-PHENYL-1H-PYRAZ","address":"30 FORJETT STREETPOST BOX NO 9301","city":"MUMBAI, MAHARASHTRA.","supplier":"JOHNSON & JOHNSON","supplierCountry":"BELGIUM","foreign_port":"BRUSSELS","customer":"JOHNSON & JOHNSON","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"2.5","unit":"GMS","unitRateFc":"286","totalValueFC":"859.3","currency":"EUR","unitRateINR":"25282.4","date":"01-Sep-2021","totalValueINR":"63206","totalValueInUsd":"859.3","indian_port":"BOMBAY AIR","hs_no":"29349990","bill_no":"5268720","productDescription":"API","marketType":"REGULATED MARKET","country":"BELGIUM","selfForZScoreResived":"Pharma Grade","supplierPort":"BRUSSELS","supplierAddress":"","customerAddress":"30 FORJETT STREETPOST BOX NO 9301"},{"dataSource":"API Import","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1636050600,"product":"(N.C.V) SELECTIVITY BATCH OF LAZERTINIB JNJ-73848242-AAA,T003901 4-CHLORO-N-(2METHOXY-4-MORPHOLINO-5-NITROPHENYL)PYRIMID","address":"L.B.S. MARG,,MULUND-WEST","city":"MUMBAI,MAHARASHTRA","supplier":"JOHNSON & JOHNSON","supplierCountry":"BELGIUM","foreign_port":"NA","customer":"JOHNSON & JOHNSON","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.25","unit":"GMS","unitRateFc":"1327","totalValueFC":"392.5","currency":"EUR","unitRateINR":"116908.7","date":"05-Nov-2021","totalValueINR":"29227.18","totalValueInUsd":"392.5","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"6131290","productDescription":"API","marketType":"REGULATED MARKET","country":"BELGIUM","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"L.B.S. MARG,,MULUND-WEST"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1653503400,"product":"(N.C.V) JNJ-73841937-ZCY,R605024 (LAZERTINIB MESYLATE HYDRATE) 2-PROPENAMIDE, N-[5-[[4-[4-[(DIMETHYLAMINO)METHYL]3-PHENY","address":"L.B.S. MARG,,MULUND-WEST","city":"MUMBAI,MAHARASHTRA","supplier":"JOHNSON & JOHNSON","supplierCountry":"BELGIUM","foreign_port":"NA","customer":"JOHNSON & JOHNSON","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.2","unit":"GMS","unitRateFc":"286","totalValueFC":"61.5","currency":"EUR","unitRateINR":"23780.9","date":"26-May-2022","totalValueINR":"4756.18","totalValueInUsd":"61.5","indian_port":"BOMBAY AIR","hs_no":"29349990","bill_no":"8841539","productDescription":"API","marketType":"REGULATED MARKET","country":"BELGIUM","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"L.B.S. MARG,,MULUND-WEST"}]
22-Jan-2021
26-May-2022
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Looking for 1903008-80-9 / Lazertinib API manufacturers, exporters & distributors?

Lazertinib manufacturers, exporters & distributors 1

69

PharmaCompass offers a list of Lazertinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Lazertinib manufacturer or Lazertinib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Lazertinib manufacturer or Lazertinib supplier.

PharmaCompass also assists you with knowing the Lazertinib API Price utilized in the formulation of products. Lazertinib API Price is not always fixed or binding as the Lazertinib Price is obtained through a variety of data sources. The Lazertinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Lazertinib

Synonyms

1903008-80-9, Yh-25448, Gns-1480, Yh25448, Gns1480, Jnj-73841937-aaa

Cas Number

1903008-80-9

Unique Ingredient Identifier (UNII)

4A2Y23XK11

About Lazertinib

Lazertinib is an orally available third-generation, selective inhibitor of certain forms of the epidermal growth factor receptor (EGFR) with activating mutations, including the resistance mutation T790M, exon 19 deletions (Del19), and the L858R mutation, with potential antineoplastic activity. Upon administration, lazertinib specifically and irreversibly binds to and inhibits selective EGFR mutants, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Lazertinib may inhibit programmed cell death-1 ligand 1 (PD-L1) and inflammatory cytokines in specific cancer cells harboring certain EGFR mutations. Compared to some other EGFR inhibitors, lazertinib may have therapeutic benefits in tumors with T790M- or L858R-mediated drug resistance. In addition, lazertinib penetrates the blood-brain barrier (BBB). This agent shows minimal activity against wild-type EGFR (wtEGFR), and does not cause dose-limiting toxicities, which occur during the use of non-selective EGFR inhibitors and inhibit wtEGFR. EGFR, a receptor tyrosine kinase (RTK) mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.

Lazertinib Manufacturers

A Lazertinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lazertinib, including repackagers and relabelers. The FDA regulates Lazertinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lazertinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Lazertinib Suppliers

A Lazertinib supplier is an individual or a company that provides Lazertinib active pharmaceutical ingredient (API) or Lazertinib finished formulations upon request. The Lazertinib suppliers may include Lazertinib API manufacturers, exporters, distributors and traders.

Lazertinib KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Lazertinib Drug Master File in Korea (Lazertinib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Lazertinib. The MFDS reviews the Lazertinib KDMF as part of the drug registration process and uses the information provided in the Lazertinib KDMF to evaluate the safety and efficacy of the drug.

After submitting a Lazertinib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Lazertinib API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Lazertinib suppliers with KDMF on PharmaCompass.

Lazertinib GMP

Lazertinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Lazertinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lazertinib GMP manufacturer or Lazertinib GMP API supplier for your needs.

Lazertinib CoA

A Lazertinib CoA (Certificate of Analysis) is a formal document that attests to Lazertinib's compliance with Lazertinib specifications and serves as a tool for batch-level quality control.

Lazertinib CoA mostly includes findings from lab analyses of a specific batch. For each Lazertinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Lazertinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Lazertinib EP), Lazertinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lazertinib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty